Premium
Therapeutic targeting of MLL degradation pathways in MLL‐rearranged leukemia
Author(s) -
Liang Kaiwei,
Volk Andrew G.,
Haug Jeffrey S.,
Marshall Stacy A.,
Woodfin Ashley R.,
Bartom Elizabeth T.,
Gilmore Joshua M.,
Florens Laurence,
Washburn Michael P.,
Sullivan Kelly D.,
Espinosa Joaquin M.,
Cannova Joseph,
Zhang Jiwang,
Smith Edwin R.,
Crispino John D.,
Shilatifard Ali
Publication year - 2017
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.31.1_supplement.611.1
Subject(s) - biology , leukemia , chromatin immunoprecipitation , cancer research , small hairpin rna , gene , chromosomal translocation , genetics , rna , gene expression , promoter
Chromosomal translocations of the mixed‐lineage leukemia ( MLL ) gene with various partner genes result in aggressive MLL leukemia with dismal outcomes. Despite relatively equal contributions of the rearranged allele and the remaining wild‐type allele at the mRNA level, the MLL chimeric protein is much more stable than the wild‐type MLL protein. Here, we used Multidimensional Protein Identification Technology (MudPIT) and established a pooled genome‐wide shRNA library screen to identify the factors and pathways involved in regulating the stability of the wild‐type MLL protein. Targeting wild‐type MLL degradation, through blocking of these pathways and factors, preferentially impedes MLL leukemia cell proliferation and downregulates a specific group of target genes of the MLL chimeras and their oncogenic cofactor, the Super Elongation Complex (SEC), as revealed by RNA sequencing and Chromatin Immunoprecipitation Sequencing (ChIP‐Seq). Stabilizing wild‐type MLL protein by inhibition of these pathways displaces the MLL chimera from some of its target genes and therefore relieves the cellular oncogenic addiction to MLL chimeras. Furthermore, pharmacologically inhibition of these pathways with small molecules substantially delays progression and improves survival of murine MLL‐AF9 leukemia in vivo. Therefore, disrupting the balance between wild‐type MLL and MLL chimeras by stabilization of MLL provides us with a paradigm in the development of therapies for aggressive MLL leukemia and perhaps for other cancers driven by chromosomal translocations. Support or Funding Information This study was supported by the Samuel Waxman Cancer Research Foundation to John D. Crispino and National Institute of Health grants, CA211428 to Edwin R. Smith, CA117907 to Joaquin M. Espinosa, CA101774 to John D. Crispino. and R35CA197569 to Ali Shilatifard